Inactive Instrument

Opiant Pharmaceuticals, Inc.

OPNT

US6837501039

Biotechnology & Medical Research

OPIANT PHARMACEUTICALS, INC. : Other Events (form 8-K)

January 10, 2020 at 02:37 am IST

Item 8.01 Other Events

On January 9, 2020, Opiant Pharmaceuticals, Inc.'s Chief Scientific Officer, Dr. Phil Skolnick, completed all sales and terminated the Rule 10b5-1 trading plan currently in place for him.















































                                       1
214896733 v2
--------------------------------------------------------------------------------

Latest news about Opiant Pharmaceuticals, Inc.

Indivior completes acquisition of Opiant Pharmaceuticals	02/23/02	AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	02/23/02	MT
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index	02/23/02	CI
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index	02/23/02	CI
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	02/23/02	CI
Transcript : Opiant Pharmaceuticals, Inc. - Shareholder/Analyst Call	01/23/01
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	08/23/08	MT
Indivior announces expiry of waiting period for Opiant purchase	06/23/06	AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	06/23/06	MT
Indivior Nears Acquisition of Opiant Pharmaceuticals	06/23/06	MT
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals	26/23/26	RE
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	20/23/20	MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	20/23/20	CI
Insider Sell: Opiant Pharmaceuticals	06/23/06	MT
Opiant Pharmaceuticals Completes Rolling Submission of New Drug Application for Potential Opioid Overdose Drug	23/22/23	MT
Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose	23/22/23	CI
Healthcare Shares Climb, Beating Broader Market -- Healthcare Roundup	15/22/15	DJ
Top Midday Gainers	15/22/15	MT
MarketScreener's World Press Review : November 14, 2022	14/22/14
Wall Street Set to Open Lower After Red Hot Week; Fed Gov Warns Inflation Fight Not Over	14/22/14	MT
US Futures Nudge Lower Premarket as Fed Governor Warns Inflation Fight Not Over	14/22/14	MT
Top Premarket Gainers	14/22/14	MT
Transcript : Indivior PLC, Opiant Pharmaceuticals, Inc. - M&A Call	14/22/14
Indivior buys Opiant creating "comprehensive" treatment platform	14/22/14	AN
Opiant Pharmaceuticals to Be Acquired by Indivior	14/22/14	MT

Chart Opiant Pharmaceuticals, Inc.

Duration

Period

More charts

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.65TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.62TCr
BEIGENE, LTD.	-20.90%	1.54TCr
WUXI APPTEC CO., LTD.	-46.14%	1.52TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.35TCr

Bio Therapeutic Drugs